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Abstract
Background: Sepsis is a disease with high incidence
and lethality and is accompanied by profound meta-
bolic disturbances. In mammalian methionine meta-
bolism, S-adenosylmethionine (SAM) is produced,
which is important in the synthesis of neurotransmit-
ters and glutathione and as an anti-inflammatory
agent. The degradation product and antagonist of
SAM is S-adenosylhomocysteine (SAH). In this study,
we investigated changes in methionine metabolism in
a rodent model of sepsis.
Methods: Sepsis was induced in male Wistar rats
(ns21) by intraperitoneal injection of bacterial lipo-
polysaccharide (10 mg/kg). Controls (ns18) received
vehicle only. Blood was collected by cardiac puncture
24 h later. Puncture of the suboccipital fossa was per-
formed to collect cerebrospinal fluid (CSF). Methio-
nine metabolites were measured using stable isotope
dilution tandem mass spectrometry. Plasma total
homocysteine and cysteine were measured by HPLC
using fluorescence detection. Glutathione was
assayed using a modified enzymatic microtiter plate
assay.
Results: We observed significantly higher plasma lev-
els of SAM (p-0.001) and SAM/SAH ratio (ps0.004)
in septic animals. In CSF, there was also a trend for
higher levels of SAM in septic animals (ps0.067). Oxi-
dative stress was reflected by an increase in the ratio
of oxidized/reduced glutathione in septic animals
(ps0.001).
Conclusions: Sepsis is associated with an increase in
SAM/SAH ratio in plasma and CSF in rodents. This
indicates an altered methylation potential during sep-
sis, which may be relevant for sepsis-associated
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impairment of transmethylation reactions, circulation
and defense against oxidative stress. If verified in
humans, such findings could lead to novel strategies
for supportive treatment of sepsis, as methionine
metabolism can easily be manipulated by dietary
strategies.
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Introduction
Despite considerable efforts, sepsis is still one of the
leading causes of death in intensive care units (1, 2).
Sepsis markedly alters metabolism, in particular
amino acid and protein metabolism (3, 4). During
transmethylation of methionine to homocysteine,
methionine is transferred to S-adenosylmethionine
(SAM; Figure 1). SAM occupies a central position in
the metabolism of all cells as an essential methyl
donor to maintain normal methylation of DNA, RNA,
proteins, phospholipids, histones and neurotransmit-
ters, as well as a multitude of small molecules nec-
essary for normal cell function and viability. SAM can
control the expression of multiple genes in a dose-
dependent manner by binding to riboswitches that
control transcription and translation (5). In sepsis,
SAM inhibits the decrease in circulating immuno-
active cells and the increase in the pro-inflammatory
cytokine interleukin-1 (IL-1) (6). The degradation prod-
uct of SAM is S-adenosylhomocysteine (SAH), which
is reversibly hydrolyzed to homocysteine (Hcy). Hcy
can be transsulfurated into cystathionine via cysta-
thionine b-synthase (CBS). Furthermore, via cysta-
thionine g-lyase, cystathionine is catalyzed to cysteine
as a component of glutathione (GSX), which is impor-
tant for the cellular redox system. As an alternative to
transsulfuration, Hcy can be recycled by remethyla-
tion to methionine via methionine synthase. This
requires vitamin B12 and 5-methyltetrahydrofolate,
which is synthesized by 5,10-methylenetetrahydro-
folate reductase (MTHFR) from 5,10-methylenetetra-
hydrofolate. In addition, the latter folate derivative is
necessary for nucleic acid synthesis. Supraphysiolo-
gical doses of vitamin B12 and vitamin B2, a cofactor
of MTHFR, are beneficial in sepsis (7, 8). Lipopolysac-
charide (LPS) is a major cell-wall constituent of Gram-
negative bacteria. The LPS model of sepsis induction
involves binding to the LPS-binding protein, endothe-
lial activation through a receptor complex of Toll-like
receptor 4, the LPS receptor molecule (CD14), and
MD2, and early activation of nuclear factor-kB, finally
resulting in the production of various pro-inflamma-
tory mediators and possibly cell injury (9).
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Figure 1 Methionine metabolism.
The sulfur-containing amino acid methionine is activated to
S-adenosylmethionine (AdoMet), which is an ubiquitous
methyl-group donor. The degradation product of AdoMet is
S-adenosylhomocysteine (AdoHcys), which is hydrolyzed to
homocysteine. Homocysteine can be remethylated to methi-
onine and AdoMet via methionine synthase (MTR), which
depends on derivatives of folate and vitamin B12 as cofac-
tors. Dihydrofolate reductase (DHFR) converts folate into
5,10-methylenetetrahydrofolate, which is further converted
into 5-methyltetrahydrofolate by 5,10-methylenetetrahydro-
folate reductase (MTHFR). Alternatively, homocysteine can
be transsulfurated by vitamin B6-dependent cystathionine-
beta-synthase (CBS) and cystathionine g-lyase (CGL) to cys-
teine as a component of glutathione.
In view of the central importance of methionine
metabolism for overall cellular viability and oxidative
defense and the beneficial role of cofactors of impor-
tant enzymes of methionine metabolism during sep-
sis, we investigated the effects of sepsis on essential
components of methionine metabolism. We com-
pared SAM/SAH and oxidized/reduced glutathione
(GSSG/GSH) ratios and Hcy and cysteine levels in
LPS-treated and control rats. The SAM/SAH ratio is
important because it is an indicator of the cellular
methylation potential, as SAM and SAH are the sub-
strate and product, respectively, of essential methyl-
transferase reactions, and SAH effectively anta-
gonizes SAM-dependent transmethylation reactions.
The GSSG/GSH ratio is a common measure of cellular
redox potential, and Hcy and cysteine levels are indi-
cative of transsulfuration activity in methionine meta-
bolism (10). As central nervous system (CNS) involve-
ment is a common complication of sepsis and is asso-
ciated with higher mortality in sepsis patients (11, 12),
we also measured SAM and SAH in cerebrospinal flu-
id (CSF).
Materials and methods
Male Wistar rats (Charles River, Sulzfeld, Germany) weigh-
ing 250–300 g were housed in groups of four under standard
conditions at 22"18C and a 12-h light/dark cycle with free
access to standard food pellets (Altromin, Soest, Germany)
and tap water.
To initiate experimental sepsis, rats received LPS (0127:B8,
E. coli, 10 mg/kg) dissolved in 1 mL of 0.9% sodium chloride
intraperitoneally (i.p.; ns22). Control animals received the
vehicle (sodium chloride) alone (ns18). At 24 h after initia-
tion of experimental sepsis, animals were anesthetized i.p.
with ketamine (75 mg/kg) and xylazine hydrochloride (10
mg/kg). Puncture of the suboccipital fossa was performed to
collect approximately 100 mL of CSF. Blood (1 mL) was col-
lected by cardiac puncture and stored in EDTA-containing
vials. All animals were sacrificed by decapitation. Septic and
control animals were treated in parallel in groups of 10 each.
The animal experiments were approved by the local
government.
To obtain plasma, blood was centrifuged for 15 min at
4000 g and 48C immediately after collection. The supernatant
was deproteinized by addition of 10% perchloric acid. All ali-
quots were stored at –808C for 1–2 months before shipment
on dry ice. Deproteinized plasma and CSF were used for
simultaneous determination of SAM and SAH using stable
isotope dilution tandem mass spectrometry as previously
reported. The inter-assay coefficient of variation was 6.8%
for SAM and 6.9% for SAH (13). Owing to the limited
amounts of CSF available, we restricted CSF analysis to the
key parameters SAM and SAH. Plasma total Hcy and cyste-
ine were measured by HPLC using fluorescence detection.
The inter-assay coefficient of variation was 1.8% for Hcy and
3.6% for cysteine (14). GSX was assayed as total cellular
GSX, i.e., the sum of reduced and oxidized forms, using a
modified enzymatic microtiter plate assay (15, 16). Briefly,
pellets of EDTA blood were treated with sulfosalicylic acid
prior to centrifugation and freezing of the supernatant. Total
cellular GSX content was determined after addition of dithio-
bisnitrobenzoic acid to aliquots of the supernatant (final con-
centration 10 mM) by measuring the change in absorbance
at 405 nm for 10 min. To determine GSSG, GSH was deri-
vatized with 2.5% 2-vinylpyridine for 60 min prior to kinetic
measurement. Protein content was determined using the
Lowry method (17). GSH was calculated as the difference
between total GSX and GSSG.
Statistics
Differences between groups were calculated using a two-
sided t-test, and correlation analysis was performed using
Pearson’s correlation coefficient. A p-value of F0.05 was
considered statistically significant.
Results
Experimental induction of sepsis led to typical symp-
toms such as piloerection, tachypnoea and social
withdrawal. One rat in the sepsis group died during
the observation period. All other rats survived LPS
and vehicle treatment. Thus, groups of LPS-treated
and control animals included 21 and 18 rats,
respectively.
The plasma and CSF results are listed in Table 1. In
LPS-treated rats, the plasma SAM/SAH ratio was sig-
nificantly higher (ps0.004) than in control animals
because of higher SAM levels (p-0.001). Compara-
ble, but not significantly different results were
obtained for changes in SAM (ps0.067) and SAH lev-
els in CSF. SAM levels in plasma and CSF were sig-
nificantly correlated in both septic animals (rs0.460;
ps0.041) and controls (rs0.691; ps0.006). There was
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Table 1 Comparison of LPS-treated and control animals.
Parameter Control rats (ns18) LPS-treated rats (ns21) t-Test (two-sided)
SAM, nmol/L 178.6"33.8 367.2"152.0 p-0.001
SAH, nmol/L 39.32"25.6 41.20"28.0 ps0.832
SAM/SAH ratio 6.55"3.74 11.90"6.39 ps0.004
CSF: SAM, nmol/L 324.09"159.67 420.64"141.37 ps0.067
CSF: SAH, nmol/L 25.14"25.65 22.05"21.62 ps0.702
CSF: SAM/SAH 20.17"11.20 29.87"17.35 ps0.068
Hcy, mmol/L 2.78"0.81 4.44"2.62 ps0.063
Cysteine, mmol/L 178"15 218"52 ps0.093
GSH, nmol/mg protein 216.57"70.0 102.55"38.46 p-0.001
GSSG, nmol/mg protein 59.67"58.36 117.79"77.46 ps0.022
GSSG/GSH 0.24"0.17 0.48"0.09 ps0.001
Values are reported as mean"SD.
no significant difference in Hcy or cysteine between
the groups. GSX levels were also not significantly
different. However, relative amounts of GSSG were
significantly higher (ps0.022) and of GSH were
significantly lower (p-0.001), so that the GSSG/GSH
ratio was significantly higher (ps0.001) in septic
animals.
In exploratory analysis of data for septic animals,
we found correlation between plasma Hcy and SAH
levels (rs0.601; ps0.011), between Hcy plasma and
total cellular GSX (rs0.633; ps0.011), and a trend
between SAM plasma and total cellular GSX
(rs0.434; ps0.064).
Discussion
Protein metabolism is markedly changed during sep-
sis, as characterized by generalized protein catabo-
lism in muscle and enhanced elimination of amino
acids from the intravascular space, mainly through
the liver (3, 18). Proteolysis might contribute to the
increase in SAM observed. SAM is methyl donor for
the manifold methyltransferases. Sepsis-induced inhi-
bition of these methyltransferases may lead to
impaired SAM utilization and contribute to the
increase in SAM levels. Increased Hcy remethylation
to methionine and finally SAM during sepsis is unlike-
ly, as oxidative stress leads to lower methionine syn-
thase and betaine-Hcy S-methyltransferase activity
(19–21). In addition, we would expect Hcy levels to be
lower in septic animals if increased remethylation
occurred during sepsis. High SAM levels down-regu-
late MTHFR, a key enzyme in Hcy remethylation, mak-
ing it unlikely that remethylation is increased (22).
Finally, the increase in SAM might be due to
enhanced synthesis of SAM from methionine during
sepsis. The present data do not allow any conclusion
on the underlying mechanism.
Because SAM and SAH are the substrate and prod-
uct of essential methyltransferase reactions, and
because SAH is an effective antagonist of transme-
thylation enzymes, the SAM/SAH ratio is frequently
used as an indicator of cellular methylation potential
(23, 24). The SAM/SAH ratio of 6.55 observed for con-
trols in the current study corresponds well to SAM/
SAH ratios observed in humans in studies under
physiological conditions (24, 25). However, this ratio
increases during sepsis, indicating an increased methyl-
ation potential that influences numerous reactions in
cellular metabolism, DNA methylation, membrane
stability and neurotransmitter synthesis (26–28).
In CSF of septic rats, we also observed increased
SAM levels and a trend for an increased SAM/SAH
ratio. SAM levels in plasma and CSF were correlated
in control and LPS-treated animals, suggesting that
SAM measurement in plasma is suitable for deter-
mining SAM availability in the CNS under physiolog-
ical conditions and during sepsis.
GSX is one of the most important cellular redox
systems, and oxidative stress plays a key role in var-
ious diseases including sepsis (29–33). During sepsis
the amount of GSSG increased, the amount of GSH
decreased, and thus the GSSG/GSH ratio increased,
indicating relevant oxidative stress during sepsis. In
the liver, approximately 50% of the cysteine in GSX
is derived from Hcy via the transsulfuration pathway
(34). The positive correlation between Hcy and GSX
during sepsis, but not in controls, suggests that Hcy
is required for GSX production during sepsis (Figure
1).
Transsulfuration is enhanced by high SAM levels,
as SAM physiologically activates CBS and decreases
MTHFR activity (10, 22). Accordingly, we found a
trend for increases in Hcy and cysteine levels. Thus,
our results indicate that higher levels of SAM lead to
a higher transsulfuration rate to allow GSX synthesis
for defense of oxidative stress induced by sepsis. In
addition, oxidative stress leads to an increased Hcy
flux through the transsulfuration pathway by up-reg-
ulation of CBS activity (35) and decreased activity of
methionine synthase and betaine-Hcy S-methyltrans-
ferase (19–21). Increased transsulfuration rates during
experimentally induced sepsis were also shown by
injection of radiolabeled cysteine and methionine in
rats (36, 37).
Methionine metabolism is markedly altered during
LPS-induced sepsis in rodents. The validity of our
data is limited, as the LPS model of sepsis does not
accurately reflect human sepsis (38). Furthermore,
blood and CSF samples were taken at only one time-
point. However, the data observed encourage future
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studies of methionine metabolites in human patients
over time to explore the association between sepsis
and methionine metabolism in more detail. As methi-
onine metabolism can easily be manipulated by diet-
ary strategies such as supplementation with vitamins
or SAM, such studies could lead to strategies for addi-
tive treatment of sepsis.
References
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G,
Carcillo J, Pinsky MR. Epidemiology of severe sepsis in
the United States: analysis of incidence, outcome, and
associated costs of care. Crit Care Med 2001;29:1303–10.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epide-
miology of sepsis in the United States from 1979
through 2000. N Engl J Med 2003;348:1546–54.
3. Druml W, Heinzel G, Kleinberger G. Amino acid kinetics
in patients with sepsis. Am J Clin Nutr 2001;73:908–13.
4. Breuille D, Arnal M, Rambourdin F, Bayle G, Levieux D,
Obled C. Sustained modifications of protein metabolism
in various tissues in a rat model of long-lasting sepsis.
Clin Sci (Lond) 1998;94:413–23.
5. Loenen WA. S-Adenosylmethionine: jack of all trades
and master of everything? Biochem Soc Trans 2006;34:
330–3.
6. Garcia-Alvarez F, Navarro-Zorraquino M, Larrad L, Sali-
nas JC, Sousa R, Pastor C, et al. S-adenosylmethionine
immunomodulator treatment in sepsis. Int J Surg Invest
2000;2:9–15.
7. Toyosawa T, Suzuki M, Kodama K, Araki S. Highly puri-
fied vitamin B2 presents a promising therapeutic strat-
egy for sepsis and septic shock. Infect Immun 2004;72:
1820–3.
8. Greenberg SS, Xie J, Zatarain JM, Kapusta DR, Miller
MJ. Hydroxocobalamin (vitamin B12a) prevents and
reverses endotoxin-induced hypotension and mortality
in rodents: role of nitric oxide. J Pharmacol Exp Ther
1995;273:257–65.
9. Dauphinee SM, Karsan A. Lipopolysaccharide signaling
in endothelial cells. Lab Invest 2006;86:9–22.
10. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfura-
tion. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs
B, Kinzler K, Vogelstein B, editors. The metabolic and
molecular bases of inherited disease. New York:
McGraw-Hill, 2001:2007–56.
11. Sprung CL, Peduzzi PN, Shatney CH, Schein RM, Wilson
MF, Sheagren JN, et al. Impact of encephalopathy on
mortality in the sepsis syndrome. The Veterans Admin-
istration Systemic Sepsis Cooperative Study Group. Crit
Care Med 1990;18:801–6.
12. Eidelman LA, Putterman D, Putterman C, Sprung CL. The
spectrum of septic encephalopathy. Definitions, etiolo-
gies, and mortalities. J Am Med Assoc 1996;275:470–3.
13. Struys EA, Jansen EE, de Meer K, Jakobs C. Determi-
nation of S-adenosylmethionine and S-adenosylhomo-
cysteine in plasma and cerebrospinal fluid by stable-
isotope dilution tandem mass spectrometry. Clin Chem
2000;46:1650–6.
14. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid
high-performance liquid chromatographic assay for total
homocysteine levels in human serum. J Chromatogr
1991;565:441–6.
15. Baker MA, Cerniglia GJ, Zaman A. Microtiter plate assay
for the measurement of glutathione and glutathione
disulfide in large numbers of biological samples. Anal
Biochem 1990;190:360–5.
16. Tietze F. Enzymic method for quantitative determination
of nanogram amounts of total and oxidized glutathione:
applications to mammalian blood and other tissues.
Anal Biochem 1969;27:502–22.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein
measurement with the Folin phenol reagent. J Biol
Chem 1951;193:265–75.
18. De Bandt JP, Cynober L. Therapeutic use of branched-
chain amino acids in burn, trauma, and sepsis. J Nutr
2006;136:308S–13S.
19. McCaddon A, Regland B, Hudson P, Davies G. Functional
vitamin B(12) deficiency and Alzheimer disease. Neurol-
ogy 2002;58:1395–9.
20. Olteanu H, Banerjee R. Human methionine synthase
reductase, a soluble P-450 reductase-like dual flavopro-
tein, is sufficient for NADPH-dependent methionine syn-
thase activation. J Biol Chem 2001;276:35558–63.
21. Miller CM, Szegedi SS, Garrow TA. Conformation-
dependent inactivation of human betaine-homocysteine
S-methyltransferase by hydrogen peroxide in vitro. Bio-
chem J 2005;392:443–8.
22. Selhub J, Miller JW. The pathogenesis of homocystei-
nemia: interruption of the coordinate regulation by S-
adenosylmethionine of the remethylation and trans-
sulfuration of homocysteine. Am J Clin Nutr 1992;55:
131–8.
23. Cantoni GL. The role of S-adenosylhomocysteine in the
biological utilization of S-adenosylmethionine. Prog Clin
Biol Res 1985;198:47–65.
24. Hoffman DR, Cornatzer WE, Duerre JA. Relationship
between tissue levels of S-adenosylmethionine, S-ade-
nylhomocysteine, and transmethylation reactions. Can J
Biochem 1979;57:56–65.
25. Helland S, Ueland PM. Effect of 29-deoxycoformycin infu-
sion on S-adenosylhomocysteine hydrolase and the
amount of S-adenosylhomocysteine and related com-
pounds in tissues of mice. Cancer Res 1983;43:4142–7.
26. Detich N, Hamm S, Just G, Knox JD, Szyf M. The methyl
donor S-adenosylmethionine inhibits active demethyl-
ation of DNA: a candidate novel mechanism for the phar-
macological effects of S-adenosylmethionine. J Biol
Chem 2003;278:20812–20.
27. Garcea R, Daino L, Pascale R, Simile MM, Puddu M, Rug-
giu ME, et al. Protooncogene methylation and expres-
sion in regenerating liver and preneoplastic liver nodules
induced in the rat by diethylnitrosamine: effect of vari-
ations of S-adenosylmethionine:S-adenosylhomocys-
teine ratio. Carcinogenesis 1989;10:1183–92.
28. Rodenhiser D, Mann M. Epigenetics and human disease:
translating basic biology into clinical applications. Can
Med Assoc J 2006;174:341–8.
29. Butterfield DA. Oxidative stress in neurodegenerative
disorders. Antioxid Redox Signal 2006;8:1971–3.
30. Storz P. Reactive oxygen species in tumor progression.
Front Biosci 2005;10:1881–96.
31. Tsuru R, Hojo Y, Gama M, Mizuno O, Katsuki T, Shimada
K. Redox imbalance in patients with coronary artery dis-
ease showing progression of atherosclerotic lesions. J
Cardiol 2006;48:183–91.
32. Crimi E, Sica V, Slutsky AS, Zhang H, Williams-Ignarro
S, Ignarro LJ, et al. Role of oxidative stress in experi-
mental sepsis and multisystem organ dysfunction. Free
Radic Res 2006;40:665–72.
33. Cighetti G, Paroni R, Marzorati S, Borotto E, Giudici R,
Magnanini G, et al. Evaluation of oxidative stress in
serum of critically ill patients by a commercial assay and
gas chromatography-mass spectrometry. Clin Chem
2005;51:1515–7.
34. Mosharov E, Cranford MR, Banerjee R. The quantitative-
ly important relationship between homocysteine meta-
bolism and glutathione synthesis by the transsulfuration
1402 Semmler et al.: Methionine metabolism in sepsis
Article in press - uncorrected proof
pathway and its regulation by redox changes. Biochem-
istry 2000;39:13005–11.
35. Singh S, Madzelan P, Banerjee R. Properties of an un-
usual heme cofactor in PLP-dependent cystathionine
beta-synthase. Nat Prod Rep 2007;24:631–9.
36. Malmezat T, Breuille D, Pouyet C, Buffiere C, Denis P,
Mirand PP, et al. Methionine transsulfuration is
increased during sepsis in rats. Am J Physiol Endocrinol
Metab 2000;279:E1391–7.
37. Malmezat T, Breuille D, Pouyet C, Mirand PP, Obled C.
Metabolism of cysteine is modified during the acute
phase of sepsis in rats. J Nutr 1998;128:97–105.
38. Riedemann NC, Guo RF, Ward PA. The enigma of sepsis.
J Clin Invest 2003;112:460–7.
